Drug news
EU approves Sancuso (granisetron transdermal patch) for chemotherapy induced nausea treatment.-Prostrakan
ProStrakan, a subsidiary of Kyowa Hakko Kirin, has received EC approval for Sancuso (granisetron transdermal patch) in Europe. Sancuso is indicated for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy, for a planned duration of three to five consecutive days, where oral anti-emetic administration is complicated by factors making swallowing difficult.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.